KalVista Pharmaceuticals, Inc. (FRA:4XC1)
Germany · Delayed Price · Currency is EUR 12.70
+0.30 (2.42%)
At close: Jan 30, 2026
KalVista Pharmaceuticals Revenue
KalVista Pharmaceuticals had revenue of $13.69M USD in the quarter ending September 30, 2025.
Revenue (ttm)
$1.25M
Revenue Growth
n/a
P/S Ratio
532.74
Revenue / Employee
$4.62K
Employees
270
Market Cap
664.12M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | - | - | - |
| Apr 30, 2024 | - | - | - |
| Apr 30, 2023 | - | - | - |
| Apr 30, 2022 | - | - | - |
| Apr 30, 2021 | - | - | - |
| Apr 30, 2020 | 12.69M | -3.44M | -21.31% |
| Apr 30, 2019 | 16.13M | 7.73M | 92.13% |
| Apr 30, 2018 | 8.39M | 6.89M | 458.11% |
| Apr 30, 2017 | 1.50M | -629.00K | -29.49% |
| Apr 30, 2016 | 2.13M | 2.10M | 7,255.17% |
| Dec 31, 2015 | 29.00K | - | - |
| Dec 31, 2014 | 29.00K | -386.00K | -93.01% |
| Dec 31, 2013 | 415.00K | -1.12M | -73.02% |
| Dec 31, 2012 | 1.54M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Paul Hartmann AG | 2.44B |
| FRoSTA Aktiengesellschaft | 652.00M |
| Maschinenfabrik Berthold Hermle AG | 469.42M |
| Südwestdeutsche Salzwerke AG | 347.96M |
| EUROKAI GmbH & Co. KGaA | 262.47M |
| Northern Data AG | 200.27M |
| Berliner Effektengesellschaft AG | 174.56M |
| Sedlmayr Grund und Immobilien AG | 139.01M |